美国 · SEC FORM 4
Centessa Pharmaceuticals plc
CNTA · — · CIK 0001847903 · Healthcare
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
25 同一窗口内观察到的 Form 4 交易行
8 sales · 17 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-05-16 · GOYAL ARJUN · $5.3M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Accardi Mario AlbertoChief Executive Officer
○○
Medicxi Co-Invest I LP; Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Secondary Co-Invest I LP; Medicxi Secondary I GP Ltd.; Medicxi Secondary I LP; Medicxi Ventures I GP Ltd; Medicxi Ventures I LP; Medicxi Ventures Management (Jersey) LtdTenPercentOwner
▼
INDEX VENTURES LIFE VI (JERSEY) L.P.; Index Venture Life Associates VI Ltd; Yucca (Jersey) SLPTenPercentOwner
▼
HUSSAIN IQBAL JChief Legal Officer
○
Bush Tia LChief Technology & Quality Ofc
○
Crowley John JChief Financial Officer
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 6 additional owner(s) remain in Form 4 申报证据.
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-05-16 · GOYAL ARJUN.
近期 Form 4 活动
0买入
27卖出
44其他 Form 4 交易行
34SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出8 sale line(s) · 仅供背景
其他17 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-05-16 | GOYAL ARJUN | 买入 (P) | Ordinary Shares | 417,646 | USD 12.73 | USD 5,316,634 | SEC 申报 ↗ |
| 2025-05-15 | GOYAL ARJUN | 买入 (P) | Ordinary Shares | 44,939 | USD 12.24 | USD 550,053 | SEC 申报 ↗ |
| 2022-06-24 | SAHA SAURABH | 买入 (P) | Ordinary Shares | 10,000 | USD 4.63 | USD 46,300 | SEC 申报 ↗ |
| 2022-02-02 | SAHA SAURABH | 买入 (P) | Ordinary Shares | 5,000 | USD 9.74 | USD 48,700 | SEC 申报 ↗ |
| 2022-01-28 | GRAINGER DAVID J | 买入 (P) | Ordinary Shares | 27,500 | USD 9.05 | USD 248,875 | SEC 申报 ↗ |
| 2021-12-02 | Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Ventures Management (Jersey) Ltd | 买入 (P) | Ordinary Shares | 34,326 | USD 12.82 | USD 440,059 | SEC 申报 ↗ |
| 2021-12-02 | De Rubertis Francesco | 买入 (P) | Ordinary Shares | 34,326 | USD 12.82 | USD 440,059 | SEC 申报 ↗ |
| 2021-12-01 | Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Ventures Management (Jersey) Ltd | 买入 (P) | Ordinary Shares | 60,304 | USD 12.62 | USD 761,036 | SEC 申报 ↗ |
| 2021-12-01 | De Rubertis Francesco | 买入 (P) | Ordinary Shares | 60,304 | USD 12.62 | USD 761,036 | SEC 申报 ↗ |
| 2021-11-30 | Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Ventures Management (Jersey) Ltd | 买入 (P) | Ordinary Shares | 36,847 | USD 11.62 | USD 428,162 | SEC 申报 ↗ |
| 2021-11-30 | De Rubertis Francesco | 买入 (P) | Ordinary Shares | 36,847 | USD 11.62 | USD 428,162 | SEC 申报 ↗ |
| 2021-11-29 | Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Ventures Management (Jersey) Ltd | 买入 (P) | Ordinary Shares | 56,706 | USD 11.70 | USD 663,460 | SEC 申报 ↗ |
| 2021-11-29 | De Rubertis Francesco | 买入 (P) | Ordinary Shares | 56,706 | USD 11.70 | USD 663,460 | SEC 申报 ↗ |
| 2021-11-26 | Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Ventures Management (Jersey) Ltd | 买入 (P) | Ordinary Shares | 11,817 | USD 11.34 | USD 134,005 | SEC 申报 ↗ |
| 2021-11-26 | De Rubertis Francesco | 买入 (P) | Ordinary Shares | 11,817 | USD 11.34 | USD 134,005 | SEC 申报 ↗ |
Form 4 申报证据
71 transaction lines in the latest 365-day window; 384 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-24 | Weinhoff Gregory M | D (D) | Ordinary Shares | 65,925 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Medicxi Co-Invest I LP; Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Secondary Co-Invest I LP; Medicxi Secondary I GP Ltd.; Medicxi Secondary I LP; Medicxi Ventures I GP Ltd; Medicxi Ventures I LP; Medicxi Ventures Management (Jersey) Ltd | 卖出 (S) | Ordinary Shares | 19,963,157 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Kanes Stephen | D (D) | Ordinary Shares | 120,000 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-24 | Weinhoff Gregory M | D (D) | Ordinary Shares | 65,925 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Medicxi Co-Invest I LP; Medicxi Growth Co-Invest I LP; Medicxi Growth I GP Ltd; Medicxi Growth I LP; Medicxi Secondary Co-Invest I LP; Medicxi Secondary I GP Ltd.; Medicxi Secondary I LP; Medicxi Ventures I GP Ltd; Medicxi Ventures I LP; Medicxi Ventures Management (Jersey) Ltd | 卖出 (S) | Ordinary Shares | 19,963,157 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Kanes Stephen | D (D) | Ordinary Shares | 120,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | INDEX VENTURES LIFE VI (JERSEY) L.P.; Index Venture Life Associates VI Ltd; Yucca (Jersey) SLP | 卖出 (S) | Ordinary Shares | 9,961,789 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | HUSSAIN IQBAL J | D (D) | Ordinary Shares | 123,145 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | GOYAL ARJUN | D (D) | Ordinary Shares | 462,585 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Deferiere Raphael | D (D) | Ordinary Shares | 11,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | De Rubertis Francesco | D (D) | Ordinary Shares | 19,963,157 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Crowley John J | D (D) | Ordinary Shares | 45,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Bush Tia L | D (D) | Ordinary Shares | 147,954 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Anderson Karen M. | D (D) | Ordinary Shares | 62,085 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-24 | Accardi Mario Alberto | D (D) | Ordinary Shares | 243,282 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-01 | Accardi Mario Alberto | 代扣税 (F) | Ordinary Shares | 604 | USD 39.42 | USD 23,810 | SEC 申报 ↗ |
| 2026-03-26 | Anderson Karen M. | 卖出 (S) | Ordinary Shares | 41,076 | USD 30.12 | USD 1,237,209 | SEC 申报 ↗ |
| 2026-03-26 | Anderson Karen M. | 期权行权／转换 (M) | Ordinary Shares | 41,076 | USD 8.01 | USD 329,019 | SEC 申报 ↗ |
| 2026-03-26 | Weinhoff Gregory M | 卖出 (S) | Ordinary Shares | 23,998 | USD 30.00 | USD 719,940 | SEC 申报 ↗ |
| 2026-03-26 | Weinhoff Gregory M | 期权行权／转换 (M) | Ordinary Shares | 23,998 | USD 3.85 | USD 92,392 | SEC 申报 ↗ |
| 2026-03-17 | Anderson Karen M. | 卖出 (S) | Ordinary Shares | 10,043 | USD 28.10 | USD 282,208 | SEC 申报 ↗ |
| 2026-03-17 | Anderson Karen M. | 期权行权／转换 (M) | Ordinary Shares | 10,043 | USD 4.01 | USD 40,272 | SEC 申报 ↗ |
| 2026-03-16 | Anderson Karen M. | 卖出 (S) | Ordinary Shares | 64,768 | USD 28.21 | USD 1,827,105 | SEC 申报 ↗ |
| 2026-03-16 | Anderson Karen M. | 期权行权／转换 (M) | Ordinary Shares | 64,768 | USD 4.01 | USD 259,720 | SEC 申报 ↗ |
| 2026-03-13 | Anderson Karen M. | 卖出 (S) | Ordinary Shares | 120,029 | USD 26.25 | USD 3,150,585 | SEC 申报 ↗ |
| 2026-03-13 | Anderson Karen M. | 期权行权／转换 (M) | Ordinary Shares | 109,398 | USD 3.99 | USD 436,258 | SEC 申报 ↗ |
| 2026-03-13 | Weinhoff Gregory M | 卖出 (S) | Ordinary Shares | 73,196 | USD 26.33 | USD 1,927,363 | SEC 申报 ↗ |
| 2026-03-13 | Anderson Karen M. | 卖出 (S) | Ordinary Shares | 120,029 | USD 26.25 | USD 3,150,585 | SEC 申报 ↗ |
| 2026-03-13 | Anderson Karen M. | 期权行权／转换 (M) | Ordinary Shares | 109,398 | USD 4.01 | USD 438,686 | SEC 申报 ↗ |
| 2026-02-02 | Weinhoff Gregory M | 奖励／授予 (A) | Ordinary Shares | 31,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-02 | Kanes Stephen | 奖励／授予 (A) | Ordinary Shares | 120,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-02 | HUSSAIN IQBAL J | 卖出 (S) | Ordinary Shares | 38,951 | USD 25.15 | USD 979,618 | SEC 申报 ↗ |
| 2026-02-02 | HUSSAIN IQBAL J | 奖励／授予 (A) | Ordinary Shares | 60,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CNTA |
| CIK | 0001847903 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 384 transaction lines from 2021-05-27 to 2026-06-24 43 P purchase lines · 139 S sale lines · 202 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.